Short term fingolimod treatment decreases soluble VLA 4 levels in MS patients
2014; Elsevier BV; Volume: 275; Issue: 1-2 Linguagem: Inglês
10.1016/j.jneuroim.2014.08.610
ISSN1872-8421
AutoresErdem Tüzün, Canan Ulusoy, Selin Turan, Arda Örçen, Berrak Yetimler, Deniz Akbaş-Demir, Melike Küçükerden, Hazal Haytural, Recai Türkoğlu,
Tópico(s)Immune Response and Inflammation
ResumoMultiple sclerosis (MS) is an immune mediated disorder of the central nervous system. T-cells and other immune effector cells play crucial roles in MS pathogenesis by crossing the brain–blood barrier and consequently destroying the myelin sheat and axons. Fingolimod (FTY720) is an oral sphingosine-1-phosphate (S1P) receptor modulator, approved for treatment of MS. Resting T and B lymphocytes express elevated levels of S1P receptor and lymphocyte migration from the lymphoid organs to the brain depends on the activity of this receptor.
Referência(s)